MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1

Neoplasma

Volumn 61, Issue 6, 2014, Pages 680-689

  Gao, C ^a   Peng, F H ^a   Peng, L K ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Autophagy; Clear cell renal cell carcinoma; Heme oxygenase 1; miR 200c; Resistance

Indexed keywords

BECLIN 1; HEME OXYGENASE 1; IMATINIB; MESSENGER RNA; MICRORNA; MICRORNA 141; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 492; MICROTUBULE ASSOCIATED PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 1A 1B LIGHT CHAIN 3 PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; SORAFENIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CARBANILAMIDE DERIVATIVE; MIRN200 MICRORNA, HUMAN; NICOTINAMIDE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; DNA EXTRACTION; DNA METHYLATION; DRUG POTENTIATION; DRUG TARGETING; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LUCIFERASE ASSAY; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; RENAL CELL CARCINOMA CELL LINE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; GENETICS; KIDNEY NEOPLASMS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DNA METHYLATION; HEME OXYGENASE-1; HUMANS; KIDNEY NEOPLASMS; MICRORNAS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PIPERAZINES; PROMOTER REGIONS, GENETIC; PYRIMIDINES;

EID: 84910609183     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_083     Document Type: Article

References (28)

1. OHH M, PARK CW, IVAN M, HOFFMAN MA, KIM TY, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol, 2000, 2: 423-427 http://dx.doi.org/10.1038/35017054
2. WILHELM SM, CARTER C, TANG L, WILKIE D, MCNABOLA A, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004, 64: 7099-7109 http://dx.doi.org/10.1158/0008-5472.CAN-04-1443
3. DEMETRI GD, VON MEHREN M, BLANKE CD, VAN DEN ABBEELE AD, EISENBERG B, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347: 472-480 http://dx.doi.org/10.1056/NEJMoa020461
4. RICHARDS JA, WIGMORE SJ, DEVEY LR. Heme oxygenase system in hepatic ischemia-reperfusion injury. World J Gastroenterol, 2010, 16: 6068-6078 http://dx.doi.org/10.3748/wjg.v16.i48.6068
5. BANERJEE P, BASU A, WEGIEL B, OTTERBEIN LE, MIZUMURA K, et al. Heme oxygenase-1 promotes survival of renal cancer cells through modulation of apoptosisand autophagy-regulating molecules. J Biol Chem, 2012, 287: 32113-32123 http://dx.doi.org/10.1074/jbc.M112.393140
6. DEGESE MS, MENDIZABAL JE, GANDINI NA, GUTKIND JS, MOLINOLO A, et al. Expression of heme oxygenase-1 in non-small cell lung cancer (NSCLC) and its correlation with clinical data. Lung Cancer, 2012, 77: 168-175 http://dx.doi.org/10.1016/j.lungcan.2012.02.016
7. TSAI JR, WANG HM, LIU PL, CHEN YH, YANG MC, et al. High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients. Cell Oncol (Dordr), 2012, 35: 461-471 http://dx.doi.org/10.1007/s13402-012-0105-5
8. TIBULLO D, BARBAGALLO I, GIALLONGO C, LA CAVA P, PARRINELLO N, et al. Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells. Curr Pharm Des, 2013, 19: 2765-2770 http://dx.doi.org/10.2174/1381612811319150012
9. BISHOP JA, BENJAMIN H, CHOLAKH H, CHAJUT A, CLARK DP, et al. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res, 2010, 16: 610-619 http://dx.doi.org/10.1158/1078-0432.CCR-09-2638
10. PNG KJ, YOSHIDA M, ZHANG XH, SHU W, LEE H, et al. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev, 2011, 25: 226-231 http://dx.doi.org/10.1101/gad.1974211
11. DAS S, BRYAN K, BUCKLEY PG, PISKAREVA O, BRAY IM, et al. Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. Oncogene, 2013, 32: 2927-2936 http://dx.doi.org/10.1038/onc.2012.311
12. IMAM JS, BUDDAVARAPU K, Lee-Chang JS, GANAPATHY S, CAMOSY C, et al. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene, 2010, 29: 4971-4979 http://dx.doi.org/10.1038/onc.2010.233
13. WESSELY O, AGRAWAL R, TRAN U. MicroRNAs in kidney development: lessons from the frog. RNA Biol, 2010, 7: 296-299 http://dx.doi.org/10.4161/rna.7.3.11692
14. SENANAYAKE U, DAS S, VESELY P, ALZOUGHBI W, FROHLICH LF, et al. miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. Carcinogenesis, 2012, 33: 1014-1021 http://dx.doi.org/10.1093/carcin/bgs126
15. CHANG L, GUO F, WANG Y, LV Y, HUO B, et al. MicroRNA-200c Regulates the Sensitivity of Chemotherapy of Gastric Cancer SGC7901/DDP Cells by Directly Targeting RhoE. Pathol Oncol Res, 2013
16. MANAVALAN TT, TENG Y, LITCHFIELD LM, MULUHNGWI P, Al-Rayyan N, et al. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS One, 2013, 8: e62334 http://dx.doi.org/10.1371/journal.pone.0062334
17. HOGAN LE, MEYER JA, YANG J, WANG J, WONG N, et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood, 2011, 118: 5218-5226 http://dx.doi.org/10.1182/blood-201104-345595
18. KELLY TK, DE CARVALHO DD, JONES PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol, 2010, 28: 1069-1078 http://dx.doi.org/10.1038/nbt.1678
19. TIBULLO D, BARBAGALLO I, GIALLONGO C, LA CAVA P, PARRINELLO N, et al. Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells. Curr Pharm Des, 2013, 19: 2765-2770 http://dx.doi.org/10.2174/1381612811319150012
20. LONG JS, RYAN KM. New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy. Oncogene, 2012, 31: 5045-5060 http://dx.doi.org/10.1038/onc.2012.7
21. BALAN M, PAL S. A novel CXCR3-B-induced growth-inhibitory signal in cancer cells is mediated through the regulations of Bach-1 and Nrf2 nuclear translocation. J Biol Chem, 2013
22. CORY S, HUANG DC, ADAMS JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene, 2003, 22: 8590-8607 http://dx.doi.org/10.1038/sj.onc.1207102
23. AMUNDSON SA, MYERS TG, SCUDIERO D, KITADA S, REED JC, et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res, 2000, 60: 6101-6110
24. AMARAVADI RK, Lippincott-Schwartz J, YIN XM, WEISS WA, TAKEBE N, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res, 2011, 17: 654-666 http://dx.doi.org/10.1158/1078-0432.CCR-10-2634
25. BAREFORD MD, PARK MA, YACOUB A, HAMED HA, TANG Y, et al. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res, 2011, 71: 4955-4967 http://dx.doi.org/10.1158/0008-5472.CAN-11-0898
26. ZALCKVAR E, BERISSI H, MIZRACHY L, IDELCHUK Y, KOREN I, et al. DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy. EMBO Rep, 2009, 10: 285-292 http://dx.doi.org/10.1038/embor.2008.246
27. MAIURI MC, ZALCKVAR E, KIMCHI A, KROEMER G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol, 2007, 8: 741-752 http://dx.doi.org/10.1038/nrm2239
28. KONDO Y, KANZAWA T, SAWAYA R, KONDO S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer, 2005, 5: 726-734 http://dx.doi.org/10.1038/nrc1692